Ajinomoto Bio-Pharma and Gene Tools partner on PMO therapy

Ajinomoto Bio-Pharma Services has partnered with Gene Tools, LLC. This partnership aims to increase access to phosphorodiamidate morpholino oligomers (PMOs). PMOs are unique oligonucleotide therapies. They can help treat genetic diseases like Duchenne muscular dystrophy (DMD). This partnership addresses a big problem in early-stage research. It allows for the production of purified PMOs in small amounts. Then, it connects smoothly to GLP and GMP manufacturing for clinical development.

PMOs are special oligonucleotides. They need precise manufacturing skills. Gene Tools, a top name in small-scale PMO synthesis, will offer pre-purified PMOs to researchers around the globe. Aji Bio-Pharma will use its AJIPHASE® liquid-phase tech for purification and quality control. With deep experience in large-scale GLP and GMP production, they ensure top quality. The collaboration creates a clear path. The journey begins with research. It moves through toxicology studies and ends with clinical applications.

Yasuyuki Otake, General Manager of Aji Bio-Pharma Services, highlighted the strength of the partnership. This partnership speeds up the development of new oligonucleotide therapies. High-quality PMOs are ready for every step, from discovery to clinical production. James Summerton, PMO inventor and Chief Scientist at Gene Tools, highlighted that this collaboration gives researchers confidence. It keeps things moving by advancing strong PMO candidates into clinical development.

こちらもお読みください： Taiho Pharma Exercises Exclusive License for Casdatifan

This partnership strengthens Ajinomoto Bio-Pharma Services’s plan to back oligonucleotide therapies. It helps researchers and biopharma partners turn innovative science into clinical solutions for patients more efficiently.